Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 06, 2019
Source ID
10.1093/neuonc/noz002

Entities

People

  • Alejandra M Petrilli
  • Alicja J. Copik
  • Annemarie Carlstedt
  • Christine T. Dinh
  • Cristina Fernandez-valle
  • Denise Yan
  • Fred F. Telischi
  • Helen Morrison
  • Jackson Nagamoto
  • Jeremie Vitte
  • Jie Huang
  • Joanna Kirkpatrick
  • Juan I Young
  • Julia N. Soulakova
  • Konstantin Brnjos
  • Long-Sheng Chang
  • Marco Giovannini
  • Maria Clara Franco
  • Marisa A. Fuse
  • Olena Bracho
  • Rahul Mittal
  • Rulong Shen
  • Stephani Klingeman Plati
  • Thomas Mindos
  • Xue-zhong Liu

Organizations

  • Congressionally Directed Medical Research Programs
  • Fritz Lipmann Institute
  • National Institute on Deafness and Other Communication Disorders
  • National Institutes of Health
  • Nationwide Children's Hospital
  • Ohio State University
  • UCLA David Geffen School of Medicine
  • University of Central Florida
  • University of Miami